Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Rhea-AI Summary

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, will host its Q2 2025 earnings call on August 6, 2025 at 4:30 p.m. ET. The company, which maintains a pipeline of seven brain disease programs including three in clinical stages, will present financial results and provide a business update.

The event will be accessible via webcast through the company's website at www.neumoratx.com, with a replay available for 30 days post-event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.

News Market Reaction

-2.12%

60 alerts

-2.12% News Effect

+29.8% Peak Tracked

-5.8% Trough Tracked

-$8M Valuation Impact

$380M Market Cap

1.1x Rel. Volume

On the day this news was published, NMRA declined 2.12%, reflecting a moderate negative market reaction. Argus tracked a peak move of +29.8% during that session. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $380M at that time.

Data tracked by StockTitan Argus on the day of publication.

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update.

A live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com

FAQ

When will Neumora Therapeutics (NMRA) report Q2 2025 earnings?

Neumora Therapeutics will report Q2 2025 earnings on Wednesday, August 6, 2025 at 4:30 p.m. ET via conference call and webcast.

How can investors access Neumora Therapeutics' Q2 2025 earnings call?

Investors can access the earnings call through a live webcast on Neumora's website (www.neumoratx.com) in the events and presentations section. A replay will be available for 30 days.

How many drug development programs does Neumora Therapeutics have?

Neumora Therapeutics has seven brain disease programs in its therapeutics pipeline, with three of them in clinical stages.

What time should participants register for Neumora's Q2 2025 earnings call?

Participants should register for the conference call at least 10 minutes prior to the 4:30 p.m. ET start time.